ARTICLE | Clinical News
AnaptysBio's asthma therapy improves eosinophil count and lung function in Phase IIa
September 28, 2018 6:14 PM UTC
AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial to treat severe eosinophilic asthma showing that etokimab (formerly ANB020) improved eosinophil count and lung function vs. placebo.
A single 300 mg dose of IV etokimab led to placebo-adjusted reductions from baseline in blood eosinophil count of 31% at day two and of 46% at day 64. Etokimab also led to placebo-adjusted improvements in forced expiratory volume in 1 second (FEV1) of 8% at day two and of 11% at day 64. Etokimab was generally well tolerated with no serious adverse events reported...
BCIQ Company Profiles
BCIQ Target Profiles